Digital Mental Health: A Narrative Review of FDA-Authorized Products for Psychiatric Treatment and Diagnostic Support
Brain Sciences · 28.05.2026 · 16 (6) · 576
DOI: 10.3390/brainsci16060576 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 28.05.2026. Verfasst von Jehad Albitar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To identify FDA-authorized prescription or clinician-directed digital mental health products, including applications and software-enabled devices, for psychiatric treatment or diagnostic support.
Methods
FDA Medical Device Databases were searched for records associated with nine product codes relevant to digital mental health. Eligible records were consolidated into distinct product families. Peer-reviewed literature and FDA documentation were reviewed to characterize indications, authorization pathways, and the quality of supporting evidence.
Results
Sixteen digital mental health products and software-enabled devices authorized by the FDA met the inclusion criteria. Twelve products supported treatment for substance use disorders, insomnia, attention-deficit/hyperactivity disorder (ADHD), posttraumatic stress disorder (PTSD)-related conditions, major depressive disorder, generalized anxiety disorder, and postpartum depression. Four products provided diagnostic support for ADHD or autism spectrum disorder. Authorization was granted through either 510(k) clearance or De Novo classification, with considerable variation in the quantity, independence, and clinical relevance of supporting evidence.
Conclusions
FDA marketing authorization does not uniformly indicate clinical effectiveness. Because 510(k) clearance, De Novo classification, and premarket approval (PMA) reflect distinct regulatory standards, clinicians should interpret digital mental health products in the context of the specific authorization pathway, product indication, and supporting evidence base.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA.
ORCID-Profile: Krista Ulisse, Christopher Feghali, Dorothy van Oppen, Daniel Elswick
Zitieren
APA
Albitar, J., Ulisse, K., Feghali, C., van Oppen, D., Zell, M., & Elswick, D. (2026). Digital Mental Health: A Narrative Review of FDA-Authorized Products for Psychiatric Treatment and Diagnostic Support. Brain Sciences, 16(6), 576. https://doi.org/10.3390/brainsci16060576
Vancouver
Albitar J, Ulisse K, Feghali C, van Oppen D, Zell M, Elswick D. Digital Mental Health: A Narrative Review of FDA-Authorized Products for Psychiatric Treatment and Diagnostic Support. Brain Sciences. 2026;16(6):576. doi:10.3390/brainsci16060576
BibTeX
@article{Albitar2026,
author = {Albitar, Jehad and Ulisse, Krista and Feghali, Christopher and van Oppen, Dorothy and Zell, Matthew and Elswick, Daniel},
title = {Digital Mental Health: A Narrative Review of FDA-Authorized Products for Psychiatric Treatment and Diagnostic Support},
journal = {Brain Sciences},
year = {2026},
volume = {16},
number = {6},
pages = {576},
doi = {10.3390/brainsci16060576}
}
EUVIMED